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1 Abstract
Populations can evolve in order to adapt to external changes. The capacity
to evolve and adapt makes successful treatment of infectious diseases and can-
cer difficult. Indeed, therapy resistance has quickly become a key challenge for
global health. Therefore, ideas of how to control evolving populations in order
to overcome this threat are valuable. Here we use the mathematical concepts of
stochastic optimal control to study what is needed to control evolving popula-
tions. Following established routes to calculate control strategies, we first study
how a polymorphism can be maintained in a finite population by adaptively
tuning selection. We then introduce a minimal model of drug resistance in a
stochastically evolving cancer cell population and compute adaptive therapies,
where decisions are based on monitoring the response of the tumor, which can
outperform established therapy paradigms. For both case studies, we demon-
strate the importance of high-resolution monitoring of the target population in
order to achieve a given control objective: to control one must monitor.
• stochastic optimal control, adaptive cancer therapy, decision-making un-
der uncertainty
2 Introduction
The progression of cancer is an evolutionary process of cells driven by genetic
alterations and strong selective forces [1, 2]. The continued failure of cancer
therapies to significantly reduce mortality, despite a host of new targeted can-
cer drugs, is largely caused by the emergence of drug resistance [3]. Cancer
therapy faces a real dilemma: the more effective a new treatment is at killing
cancerous cells, the more selective pressure it provides for those cells resistant
to the drug to take over the cancer population in a process called competitive
release [4, 5].
A genetic innovation conferring resistance can either be already present as
standing variation or in close evolutionary reach, via de novo mutations. The
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probability of these events is directly proportional to the genetic diversity of the
tumor. Therefore, resistance is a problem especially for genetically heterogenous
cancers [6]. This diversity can be the result of a variable microenvironment,
with different pockets of acidity, blood supply and geometrical constraints of
surrounding tissue [3]. Also, late stage cancers not only carry the cumulative
archaeological record of their evolutionary history [7] but can also become ge-
netically unstable and fall victim to chromothripsis [8], kataegis [9] and other
disruptive mutational processes [10, 11]. Thus, the probability of treatment suc-
cess is higher in genetically homogenous and/or early stage cancers [12]. Taken
together, these considerations place emphasis on early detection of tumors.
In cases where early detection is not achieved, the pertinent question is how to
avoid treatment failure in the presence of genetic heterogeneity, which seems
to be the norm for most solid cancers. One obvious attempt is to make treat-
ments more complex and thus put the resistance mechanisms out of reach of
the tumor. In combination therapy, the tumor is simultaneously treated with
two or more drugs that would require different, possibly mutually exclusive,
escape mechanisms for cells to become resistant. This approach has proven to
be very successful in the treatment of HIV, where drug combinations are in-
creasingly chosen based on genetic screens of a patient’s virus for exploitable
mutations [13, 14, 15, 16]. In the context of cancer, this form of personalized
therapy is not yet widely realized, mainly because of the much richer repertoire
of genetic variation and adaptability of cancer cells and a comparable shortage
of drugs targeting distinct biological pathways. For a recent study of the con-
ditions under which combination therapy is expected to be successful in cancer,
see [17].
For application of single drugs, there are a number of studies that concentrate
on how the therapeutic protocol itself can be optimized.
It was realized that all-out maximum tolerated dose chemotherapy is not
the only, or necessarily the best, treatment strategy [18]. Alternative dosing
schedules were proposed such as drug holidays, metronome therapy [19] and
adaptive therapy [20]. The realization of Gatenby et al. in [20] is that cancer,
as a dynamic evolutionary process, can be better controlled by dynamically
changing the therapy, depending on the response of the tumor. Their protocol of
reducing the dose while the tumor shrinks and increasing it under tumor growth
showed a drastic improvement of life expectancy in mice models of ovarian
cancer [20]. Furthermore, Gatenby et al. made the important conceptual step
of reformulating cancer therapy to be not necessarily about tumor eradication,
but instead a dynamical problem where maintenance of a stable tumor size can
be preferable.
Motivated by this experiment, we conjecture that there are substantial therapy
gains in optimal applications of existing drugs, as of yet under-exploited. As a
first step towards utilizing this potential we would like to formalize the intuition
of Gatenby et al. To this extent, we aim to establish a theoretical framework for
the adaptive control of evolving populations. In particular, we connect the idea
of adaptive therapy to the paradigm of stochastic optimal control, also known as
a Markov decision problem. For other applications of stochastic control in the
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context of evolution by natural selection see [21, 22]. This is a well-established
field of research which provides not only a natural language for framing the task
of cancer therapy, but also a set of general purpose techniques to compute an
optimal control or therapy regimen for a given dynamical system and a given
objective, such as population size reduction. While we demonstrate the main
steps in this program,
we focus on the detrimental effect of imperfect information and the loss of
control it entails. Our key conceptual result can be summarized as: to control,
one must monitor.
We first introduce the concepts of stochastic optimal control using a minimal,
but non-trivial evolutionary example: how to keep a finite population poly-
morphic under Wright-Fisher evolution by influencing the selective difference
between two alleles? If perfect information about the population is available,
the polymorphism can be maintained for a very long time. We will show how
imperfect information due to finite monitoring can lead to a quick loss of control
and how some of it can be partially reclaimed by informed pre-emptive control
strategies. We then move to our main problem and introduce a minimal stochas-
tic model of drug resistance in cancer that incorporates features such as variable
population size, drug sensitive and resistant cells, a carrying capacity, mutation,
selection and genetic drift. After computing the optimal control strategies for a
few important settings under perfect information, we demonstrate the effect of
imperfect monitoring. If only the total tumor size can be monitored, we show
how a control strategy emerges that can adaptively infer, and thus exploit, the
inner tumor composition of susceptible and resistant cells.
3 Controlling evolving populations
One can think about cancer therapy as the attempt to control an evolving
population by means of drug treatment. Usually, the drug changes some of
the parameters of the evolutionary process, such as the death rate of drug-
sensitive cells. With application of the drug, one can thus actively influence the
dynamics of the stochastic process and change its direction. All this happens
with a concrete aim, such as to minimize the total tumor burden in the long
term. To introduce some of the concepts of stochastic optimal control, we use
an example with a non-trivial control task.
Imagine a bi-allelic and initially polymorphic population of constant size N
under the Wright-Fisher model of evolution [23], i.e. binomial re-sampling of the
population in each generation. The A allele confers a selective fitness advantage
of size σ = N (fA − fB)  1 over the B allele and will, without intervention,
eventually take over the entire population (see Figure 1A). Assuming mutation
to be negligible, the task at hand is to avoid, or at least delay, such a loss in
diversity. Now assume that we can change the selection coefficient externally
by a quantity u ∈ [−uc, 0] in the form σ → σ+u. Ideally, we would have |uc| >
σ, but this is not a necessary condition. In this setting, the control problem
can be stated as follows: for a population at initial frequency xA(0) = x0 =
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n0/N ∈ (0, 1), what is the optimal control protocol u¯0:T (x0) that maximizes the
probability Pa(T, x0) that the polymorphism is still alive after a time T?
u¯0:T (x0) = argmax
u0:T
Pa(T, x0), (1)
where the maximization is to be done over all possible sequences of controls
u0:T = u0u1 . . . uT (ut ∈ [−uc, 0]). Note that the stochastic nature of the process
makes the control optimal only in the sense of expected outcomes. Individual
realizations might well fall short of, or exceed, the implied mean survival time.
It is helpful to picture a large ensemble of such populations, all starting off
at frequency x0, all being individually nudged by selection according to a (yet
to be found) optimal protocol. When a trajectory hits one of the boundaries
before the final time T , it is lost. The optimal control can thus also be seen
to minimize this cost of attrition. The standard technique to solve problems of
this kind is to use a dynamic programming ansatz. Assuming that the partial
problem for some intermediate starting point (xt, t) (0 < t < T ) has already
been solved, we define the cost-to-go J(xt, t) as the expected cost to be paid
starting from xt at time t. From this definition follows a backward-recurrence
relation for J : the cost-to-go at (xt, t) is the cost-to-go one time step later, but
averaged over all possible states at that time. Which states most contribute
to that average depends, via the propagator W , on the control ut one applies
now [24]:
J(xt, t) = min
ut
∑
x′
J(x′, t+ 1) W (x′ | xt;ut), (2)
The absorbing boundary conditions take the form J(0, t) = J(1, t) = T − t.
The right hand side of eq. 2 can also include a term V (xt, ut) that describes
the potential cost to be at x and the control cost to apply u. Here, both are
assumed zero and cost is paid only at the boundaries. But it is important to
keep in mind that optimal control problems are usually about achieving a cer-
tain goal with the least expense. For Wright-Fisher evolution, the transition
matrix W can be expressed as the probability under binomial sampling to draw
n′A = N x
′ individuals of the A allele. The crucial computational advantage of
this relation is that the hard optimization in the space of all control protocols
u0:T is exchanged for a simple scalar optimization over ut. In statistical physics,
this technique is referred to as transfer-matrix method. The intuitive interpre-
tation of eq. 2 is that the decision for a control now relies on future controls
to be carried out optimally. In practice, the results of the local optimizations
(u¯(xt, t) = argminut . . . ) constitute the optimal control to be applied when the
system is at xt at time t. In many applications [24], it is also useful to consider
a receding time horizon, such that u¯(x, 0) is a stationary control.
The infinitesimal form of eq. 2 in the diffusion approximation (N → ∞, while
σ, uc fixed and τ = t/N) is called the Hamilton-Jacobi-Bellmann (HJB) equa-
tion [25, 24],
−∂τJ(x, τ) = min
uτ
x(1− x) [(σ + uτ ) ∂x + 12∂2x] J(x, τ), (3)
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together with the boundary condition for eq. 2. Instead of attempting a direct
solution of the HJB eq. 3 for the Wright-Fisher example, we will guess the solu-
tion and confirm it by direct numerical application of eq. 2 (see also Figure S4
in Supporting Information).
3.1 Optimal control of a Wright-Fisher population with
perfect monitoring
The optimal control function u¯(xt, t) maximizes the probability that a polymor-
phism is still present after a time T . In the infinite horizon time limit T →∞,
where the optimal control becomes stationary u¯(x), we expect it to also maxi-
mize the mean first passage time 〈T 〉x out of the interval 0 < x < 1 (for any x).
Because u appears linearly in eq. 3, it is clear that only the two extreme con-
trol strengths are ever used to steer the system. This particular type of control
(when control itself is free) is called bang-bang [24]. It follows that the control
profile u¯(x) will have the form of a step-function with critical frequency xc,
u¯(x) =
{
0, x < xc
−uc, x ≥ xc
⇒ σ + u¯ =
{
> 0, x < xc
< 0, x ≥ xc
. (4)
The only remaining parameter is the critical threshold xc(σ, uc). To find an
expression for the objective function Ta(xc, σ, uc), we can consider the opti-
mally controlled system as the simplest example of evolution under frequency-
dependent, piecewise constant selection σ + u¯(x). The mean first passage time
can be found analytically using standard methods for stochastic processes [26]
(see Supporting Information and Figure S4). At the correct threshold and with
strong selective forces (σ, |σ + uc|  1), the gains are substantial and the poly-
morphism can be maintained for very long times.
3.2 Loss of control due to imperfect monitoring
The main assumption made so far was that perfect information is available about
the state of the system in the form of continuous (in time), synchronous (without
delay) and exact (without error) measurements of x. These requirements are
impossible to achieve in practice, when monitoring is always imperfect. As
we will see, when the assumption of perfect information is relaxed, not only
is control over the system lost, but the control profile u¯(x) also ceases to be
optimal. Rather than turning to the theory of partially observable Markov
decision problems [27], we will use numerical analysis to demonstrate the effect
of monitoring with finite resolution in time (relaxing the first condition).
Consider the situation where measurements of the frequency x are given only
at discrete times {τi}, while no information is available during the intervals of
length ∆ = τi+1−τi. The immediate question is: given a measurement xi, what
control should one apply while waiting for the next measurement? The perfect-
information control u¯(xi) is correct only initially, and thus only in the limit
∆ → 0. But it is intuitively clear that a naive protocol, applying u¯(x0) during
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the entire interval ∆, cannot be optimal, because it does not anticipate the
dynamics of x under this regime (see the decrease in survival time in Figure 1B).
For example, for 0 < xi < xc, the initial control is u¯ = 0 and the frequency will,
on average, increase and eventually cross the threshold xc. If one could observe
the population at that point, the control should be switched to u¯ = −uc until
x crosses xc from above. The total result of the naive strategy is to amplify
fluctuations due to this over-shooting.
3.3 Playing-to-win vs. playing-not-to-lose
Without a continuous flow of observations as input, a pre-emptive control pro-
tocol u∗(τ, xi) during the interval ∆ must be pre-computed and then faithfully
carried out. In the discrete-time (Wright-Fisher evolution) setting, there are
N∆ generation updates until the next measurement and therefore 2N∆ differ-
ent protocols to choose from. However, the example above suggests to search for
the pre-emptive control in a much smaller space, namely within those protocols
that start with either u∗ = 0 or u∗ = −uc and then switch, at some later time
τc(xi,∆), to a neutral regime with u
∗ = −σ (the complexity of this space is only
2N∆). The effect of such a control scheme is to move the population to a safe
place and then try to keep it there. There are two important observations: first,
this informed control outperforms the naive protocol significantly, especially for
intermediate values of ∆ (see Figure 1B-C); second, the safe parking position
moves away from the boundary towards x = 0.5 for larger values of ∆ (see Fig-
ure S5). This shift from an aggressive control strategy under perfect information
(∆ = 0, xc close to a boundary) to a more and more conservative one (aiming
for x = 0.5 and trying to stay there) can be summarized as playing-to-win vs.
playing-not-to-lose.
A similar loss of control can be expected for other types of monitoring imper-
fections and is a general feature of stochastic optimal control. It is important
to note that the perfect-information control problem, and its solution u¯, is a
necessary starting point for the analysis. The naive control protocol above is
indeed optimal for ∆ → 0, and still a very good option for ∆  1. In most
cases, as we will see in the adaptive cancer therapy model below, finding u¯ is
challenging in itself and can be a good guidance for finding well performing
control protocols even under imperfect conditions.
4 Application to adaptive cancer therapy
With the example above – how to control a population aiming to maintain a
polymorphism – we introduced some key elements of stochastic optimal control
and the basic steps of such an analysis. Here we apply these ideas to the problem
of adaptive cancer therapy. We first introduce a minimal stochastic model of
drug resistance in cancer. For different qualitative regimens, we then find the
optimal adaptive therapy with perfect information. Finally, we extend these
ideas to the case, where only the total cell population size can be observed but
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no readout of the fractions of susceptible and resistant cells is available.
4.1 A minimal model of drug resistance in cancer
The desired features of a minimal model of drug resistance in cancer include: (i)
a variable tumor cell population size N , (ii) at least two cell types, drug-sensitive
and drug-resistant, (iii) a carrying capacity K that describes a (temporary) state
of tumor homeostasis, (iv) the possibility for mutation and selection between
the cell types. Control over the tumor can be applied via a drug that changes
the evolutionary dynamics by increasing, for example, the death rate of sensitive
cells. We will assume here, as others have done in the context of cancer [12], a
well mixed cell population where the birth (or rather duplication) rate of cells is
regulated by the carrying capacity. The dynamics of the model we have chosen
here is encapsulated in the following birth and death rates for sensitive and
resistant cells,
Bi(ns, nr) =
(1 + gi)ni
1 + gNK + s
ns
K
+ µ0(ni¯ − ni), (5)
Di(ns, nr) = ni (1 + Fi(u)), i ∈ {s, r} , s¯ = r, r¯ = s
where gs = g + s, gr = g, µ0 is the mutation rate between cell types and Fi
encodes the effect of the drug (u = 1) or its absence (u = 0) on cell type i. For
N  K, the absolute growth rates are gi − Fi. A drug effect of the form
Fs(u) = ufs and Fr(u) = (1− u)fr, (6)
renders the drug effective if fs > g + s. The value fr = 0 corresponds to
drug-resistance as such, but fr > g implies that resistant cells thrive under
the drug and are drug-addicted. Such an effect has been observed in mice with
BRAF -mutated melanoma treated with vemurafenib [28]. Altogether, sensitive
and resistant cells initially grow exponentially until the total population size
N = ns+nr ≈ K. At that stage, competition for resources, space etc. becomes
fierce. If sensitive cells have a differential growth advantage s > 0 (they might
not have to maintain an expensive resistance mechanism), resistant cells will
eventually be removed from the tumor or reduced to a small fraction (of size
µ0/s). In reality, this scenario might not materialize, as the next mutation could
propel the tumor into a new phase of exponential growth.
For the stochastic version of this process we can assume independent and in-
dividual birth and death events with the above probabilities per unit time. In
analogy to the Wright-Fisher binomial update rule, here we can use a Poisson-
like update.
ni → n′i = ni + ∆ni, with ∆ni = ∆n+i −∆n−i (7)
∆n+i ∼ Pois(Bi), ∆n−i ∼ Pois(Di), 〈∆ni〉 = Bi −Di
The total increment ∆ni follows a Skellam distribution. The diffusion approx-
imation for this system reveals the qualitatively different parameter regimes.
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When we let K →∞ while fixing the combinations γ ≡ Kg, σ ≡ Ks, µ ≡ Kµ0
and φi = Kfi and setting t = τ/K, the system is described by a Fokker-Planck
evolution equation [29] for the distribution P (xs, xr, t) with xi ≡ ni/K (see
SI text). This scaling exercise is mainly important because it allows to relate
systems with small K (100s to 1000s, as necessarily used in numerical analysis)
to systems with large K (& 108, as present in real cancers). It is important to
note that in this limit the details of the microscopic model are not important.
For example, the effects of selection or carrying capacity could be included in
the death rates, without changing the qualitative aspects of the model.
4.2 Optimal cancer therapy with perfect monitoring
With the minimal model of drug resistance in cancer introduced above we can
start the program of stochastic optimal control to compute adaptive therapy pro-
tocols. The first task is to define the goal of such a program: what is the quantity
one aims to maximize? One candidate is the total tumor population size N , the
long-term reduction of which is the goal of standard therapy [30]. Another very
important objective is to maximize the (expected) time until the cancer pro-
ceeds to the next, possibly lethal stage. This could mean the emergence of a new
cell type with a much higher carrying capacity, e.g. with metastatic potential.
We will denote this critical event simply with a ‘driver’ event or ‘metastasis’.
The rate of metastasis emergence is a combination of tumor size and the rate
ν0 (per cell and generation) for the necessary features to appear via mutation.
Earlier, the optimal control for the Wright-Fisher evolution example turned out
to be a piecewise constant function of allele frequency. Here, we need to find a
control profile u¯(ns, nr). With perfect information, we would know ns and nr at
all times and would base the control decision adaptively on these measurements.
As in eq. 1, the control objective can be expressed as
u¯0:T (ns0, nr0) = argmax
u0:T
exp
(
−ν0
T∑
t=0
(nst + nrt)
)
, (8)
where the right hand side is the probability that metastasis has not yet happened
by time T generations. Here, the control objective is a non-linear function of
the entire trajectory (ns,0:T , nr,0:T ). As such, it is the simplest manifestation of
a so-called risk-sensitive control problem [24, 31, 32]. The above formulation
assumes a finite (receding) horizon time T and also that control itself is cost-
free. In cancer therapy, especially chemotherapy, this is certainly not the case:
the side effects of treatment incur a considerable cost in terms of life-quality and
medical care. The difficulty, however, lies in quantifying these control costs in
a manner that would make them comparable to the potential costs considered
here. This important aspect is beyond the scope of this study.
The recurrence equation for the cost-to-go J(ns, nr, t) for the control objec-
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tive above is given by [32]
J(ns, nr, t) = e
−ν0(ns+nr) max
u∈{0,1}
〈J(t+ 1; u)〉 (9)
〈J(t′;u)〉 ≡
∑
n′s,n′r
J(n′s, n
′
r, t
′) W (n′s, n
′
r | ns, nr; u) (10)
with boundary condition J(T ) = 1. The (microscopic) transition matrix W
is the product of the two Skellam distributions resulting from eq. 7 (including
boundary conditions). With this equation, we can solve the dynamic program-
ming task numerically for moderate values of K. For the numerical analysis, we
have to introduce an upper bound N˜  K +√K for the population size. The
resulting control profiles for a number of different parameter regimes is shown
in Figure 2.
In the case of φr = 0, resistant cells are unaffected by the drug. If mainte-
nance of the resistance mechanism is costly (σ > 0), the only way that they
can be removed from the population is when selection can act against them.
This only happens at N ∼ K and with u = 0 (no drug). If this can take place
before the next driver typically appears (if σ = Ks  KNν0 ∼ K2ν0 ≡ ν),
then the optimal control protocol is to postpone treatment until the resistant
cells are sufficiently cleared from the system (see Fig. 2A). However, this pa-
rameter regime of very high selection against resistance and/or very low rate of
driver mutation, and therefore this therapy option, is not realistic for cancer.
For higher values of ν/σ, the optimal strategy is to apply the drug earlier (see
Fig. 2B). This procedure can lead to cycles of tumor size reduction followed by
regrowth, with the overall effect of extending the time until metastasis.
If φr > γ (and φs > γ+ σ), resistant cells are actually drug-addicted and thrive
only in its presence. Such a situation would be easy to control with perfect
information about ns and nr. For example, if mutation between cell types is
rapid (µ  1), a majority-rule is optimal (u¯(ns > nr) = 1 and u¯(nr > ns) = 0
in a fully symmetric setting, see Fig. 2C). For a lower mutation rate, the optimal
profile first tries to amplify one cell type before switching to an environment
that is now deadly for most cells present (see Fig. 2D).
The effectiveness of different therapy protocols is compared in Figure 3 with
1000 stochastic forward simulations (with K = 104) for the parameter setting
of Fig. 2D. While no therapy (u = 0) and all-out therapy (u = 1) both ulti-
mately end with the occurrence of metastasis, adaptive therapy can bring the
tumor size down to zero in the majority of cases. In metronome therapy, the
drug is applied (withheld) for fixed time intervals τon (τoff). With numerically
optimized values of time intervals, metronome therapy is quite competitive.
All these control strategies require perfect information, not only in the sense
of the earlier Wright-Fisher example (continuous, synchronous and exact), but
also in terms of the inner tumor composition N = ns + nr, which presupposes
that sensitive and resistant cells can be distinguished.
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4.3 Loss of therapy efficacy due to low-resolution moni-
toring
There are very few cases where the genetic basis for a drug-resistance mech-
anism is known and can be specifically monitored [33, 34]. In most cases the
regrowth of the tumor under the drug is observed without understanding the
exact biological processes responsible for the resistance. Here we aim to find
rational control strategies when only the total tumor cell population size can
be monitored. The adaptive therapy protocol that was applied by Gatenby et.
al in [20] (coupling the drug concentration to the tumor size) is one example of
such a strategy.
Consider the situation where only the total population size N = ns +nr can be
(perfectly) monitored, while the dynamical laws in eqs. 5-7 and all parameter
values are known. Under these circumstances, the perfect-information optimal
control profiles from the last section cannot be used directly. However, there is
still valuable information available. The response Nτ → Nτ+∆τ of the tumor
size to a control choice over a time interval ∆τ can give an indication of the
inner tumor composition. As we have seen earlier, the length of time interval
∆τ should be shorter than all other intrinsic time scales to enable control. One
plausible way to use this information is to continuously update a (posterior)
distribution P (ns, nr | N0:τ , u0:τ−∆τ ) and use it, together with u¯(ns, nr), to de-
termine the next control uτ as the one that is ‘correct’ in a majority of cases.
An entirely different possibility is to first derive an effective propagator
Weff(Nτ+∆τ | Nτ , Nτ−∆τ , uτ−∆τ ;uτ ) and then repeat the cost-to-go calcula-
tion of eqs. 9 and 10. This propagator takes into account not only the current
size Nτ , but also the last measurement Nτ−∆τ and the last control decision
uτ−∆τ . It follows from the microscopic W used in eq. 10 by integrating over
the internal degrees of freedom ns and nr at the three time points (see SI text).
Accordingly, the control profile is now a function of (Nτ−∆τ , uτ−∆τ , Nτ ). For
the parameter values leading to the majority-rule in Fig. 2C, the new control
profile is shown in Fig. S7. The drug regimen (u = 0 or 1) is maintained as long
as the tumor size decreases sufficiently. At the first sign of possible reversal, the
regimen is switched.
5 Discussion
We used stochastic control theory to quantify optimal control strategies for
models of evolving populations. We further demonstrated how control can be
maintained with finite resources, when the monitoring necessary for adaptive
control is imperfect. These strategies all depend on our ability to anticipate
evolution, i.e. on a knowledge of the relevant equations of motion and their
parameter values. For cancer, such detailed knowledge of evolutionary dynam-
ics is certainly not yet available. Sequencing technologies are facing up to the
challenge of tumor control with finite information, already accelerating progress
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in monitoring of serial biopsies of tumors, circulating tumor cells or cell-free
tumor DNA in the bloodstream [35, 36]. Once such time-resolved data become
prevalent, we can start to learn and improve dynamical tumor models and com-
pute their optimal control strategies. For instance, genetic heterogeneity within
the tumor is now becoming quantifiable from sequencing data via computa-
tional inference [37, 38, 39]. Heterogeneity and subclonal dynamics have been
found to have an impact on treatment strategy selection [40]. Furthermore, all
other available sources of clinical data, such as medical imaging, can provide
additional high-resolution information and should be integrated into a truly
personalized and data-driven tumor-control effort (see e.g. [41] for imaging data
based computational modelling of pancreatic cancer growth dynamics to guide
treatment choice and [42] for integrative analysis of imaging and genetic data).
Beyond cancer, the need to control evolving populations is a key global health
challenge as resistant strains of bacteria, viruses and parasites are spread-
ing [43, 44, 45]. Similarly, pest resistance is also posing a danger to food supplies
and needs to be contained. Any long term success in controlling evolution de-
pends, at the very least, on mastering the following components. Firstly, on a
quantitative understanding of the underlying evolutionary dynamics. Progress
in understanding is best demonstrated by predicting evolution; this has so far
proven difficult, even in the short term. Nevertheless, new population genetic
approaches applied to data are promising – see influenza strain prediction in
Ref. [46]. Secondly, the success of control will depend on the availability of a
sufficient arsenal of non-cross resistant therapeutic agents. These therapeutics
should be combined with the ability to decide an appropriate drug regimen given
the genetic and phenotypic structure of the population. Large-scale drug vs. cell
line screens are systematically pushing this component forward (see e.g. [47]).
And finally, on the ability to monitor the evolution of target population and act
rationally based on this information; the topic of this paper.
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6 Bang-bang control of Wright-Fisher
evolution
Consider the Wright-Fisher model of evolution of a bi-allelic population of
finite size N  1 with (symmetric) mutation rate µ = Nµ0 ≥ 0 and (intrinsic)
selection coefficient σ = Ns > 0. In the diffusion approximation [29, 26], the
probability distribution P (x, t) for the allele frequency x ≡ nA/N of the
A-allele changes in time according to the following Fokker-Planck
equation [23],
∂tP (x, t) =
[−∂x (σ x(1− x) + µ(1− 2x)) + 12∂2xx(1− x)] P (x, t) (11)
with boundary condition P (x, 0) = δ(x− x0). In the limit µ→ 0, consider now
the control task of maintaining an initial polymorphism 0 < x0 < 1 for as long
as possible by linearly changing the selection coefficient instantaneously in
response to and as a function of xt:
σ → σ + u(xt), u ∈ [−uc, 0] , uc > σ. (12)
The optimal control strategy u¯(x) will maximize the average survival time of
the polymorphism,
u¯ = argmax
u
〈T 〉x0 (13)
where 〈. . .〉x0 is the average over trajectories starting at x0 and the
maximization is over all functions u : [0, 1]→ [−uc, 0] , x 7→ u(x). In this
setting, using control itself does not incur a cost and does not enter the
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Figure 1: Optimal control of a finite population under Wright-Fisher evolution
in order to maintain an initial polymorphism. The intrinsic selection coefficient
is σ = 10 and control shifts selection to σ + u. (A) Sample trajectories starting
at x0 = 0.5: without control (u ≡ 0, black line) the polymorphism is lost on a
time scale of 1/σ. With optimal control under perfect information (gray line,
σ + u = 10 for x < xc ≈ 0.644, else σ + u = −20), it can be maintained for an
average of 8000 N generations. With finite monitoring (∆ = 0.1, measurements
xi at circles), naive control (u ≡ u¯(xi)), red line) is prone to over-shooting,
while pre-emptive control (blue line) tries to avoid this by switching to a neutral
regime after a certain time. (B) Loss of control under finite monitoring: as ∆
grows, so does the probability that the polymorphism is already lost at the
next measurement. Shown is the mean survival time over 5000 trajectories with
N = 104. (C) Under pre-emptive control, some of the loss of control can be
regained, especially for intermediate values of ∆.
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Figure 2: Control of a tumor cell population. (A-D) The optimal control profile
under perfect information about ns and nr for different parameters of the cancer
model. In the white areas, u¯ = 0 (no drug), whereas in the gray areas, u¯ =
1 (with drug). The arrows indicate the deterministic flow. All profiles were
calculated via eq. 9 with T = K/ν gen. and K = 500 with an absorbing
boundary at N = 750. The sample trajectories were simulated with K = 104
and controlled according to these profiles. The coloring of the trajectories shows
the temporal evolution from blue to red. (A) When selection against resistance
is stronger than driver emergence, σ  ν, the optimal protocol is to wait until
resistant cells are cleared from the system before the drug is applied. (B) For
higher driver emergence rates, the drug is applied earlier, which can lead to
cycles. (C) For drug-sensitive (φs  γ) and drug-addicted cells (φr  γ) with
high mutation (µ 1), the control in the symmetric case (φs = φr) is a simple
majority rule and very effective. (D) For smaller mutation (µ = 1), the optimal
strategy first homogenizes the tumor before trying to remove it.
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Figure 3: Comparison of cancer therapies. For the parameter setting of Fig. 2D,
different therapies are compared via 1000 forward simulations with K = 104.
Shown is the fraction of runs that have not yet developed a metastasis mutation
by time τ . All-out maximum dosage therapy (u ≡ 1) is only slightly better than
no therapy (u ≡ 0) in avoiding metastasis. Much better is metronome therapy
with τon = τoff = 0.1 K gen. with almost 70% success rate (values numerically
optimized). Adaptive therapy removes the tumor in close to 90% of runs.
maximization objective. It can be shown [24], that maximization is then to be
carried out in the smaller function space u : [0, 1]→ {−uc, 0}, where only the
extremal control values are used. This type of control is called bang-bang. It is
also evident that the optimal control strategy, maximizing the mean survival
time, will be a piecewise constant function with a single step at a threshold
xc ∈ (0, 1).
u¯(x) ≡
{
0, x < xc
−uc, x ≥ xc
(14)
If both the intrinsic selection coefficient σ, and the control strength uc are
given, then we need to optimize only a single parameter, the threshold xc.
6.1 Analytical evaluation of the mean first passage time
Under bang-bang control, the effective selection coefficient σ + u¯ is frequency
dependent but still piecewise constant. For σ > 0 and σ + uc < 0, the
population experiences an upward drift for x < xc and a downward drift for
x > xc. If the drift forces in both domains are strong (σ  1 and
σ + uc  −1), then a typical population that is still polymorphic will most
likely be in the vicinity of xc at any one point in time (see also Figure 2A in
the main text). One can then try to calculate the mean first passage time for
trajectories starting at xc. The formula can be found using standard theory of
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stochastic processes [26]. Let us momentarily re-insert an arbitrary initial
frequency x0,
〈T 〉x0 =
(∫ x0
0
y.
ψ(y)
) ∫ 1
x0
y.
′
ψ(y′)
∫ y′
0
z. ψ(z)
z(1−z) −
(∫ 1
x0
y.
ψ(y)
) ∫ x0
0
y.
′
ψ(y′)
∫ y′
0
z. ψ(z)
z(1−z)
1
2
∫ 1
0
y.
ψ(y)
(15)
with ψ(z) ≡ exp [2σz + 2uc (z − xc) Θ(z − xc)] . (16)
The mean first passage time depends on the initial point x0, which can be
either below or above xc. This will affect all the integrals, so let us write
〈T 〉x0 = 〈T 〉+x0 Θ(x0 − xc) + 〈T 〉−x0 Θ(xc − x0) (17)
with 〈T 〉±x0 =
I±0,x0 J
±
x0,1
− I±x0,1 J±0,x0
1
2 I0,1
. (18)
The integrals in this ratio can now be computed one by one. They all have
analytical solutions.
I0,x0 ≡
∫ x0
0
y.
ψ(y)
= I+0,x0Θ(x0 − xc) + I−0,x0 Θ(xc − x0) (19)
I−0,x0 =
1
2σ
(
1− e−2σx0) (20)
I+0,x0 =
1
2σ
(
1− e−2σxc)+ e2ucxc
2(σ + uc)
(
e−2(σ+uc)xc − e−2(σ+uc)x0
)
(21)
Ix0,1 ≡
∫ 1
x0
y.
ψ(y)
= I+x0,1Θ(x0 − xc) + I−x0,1 Θ(xc − x0) (22)
I−x0,1 =
1
2σ
(
e−2σx0 − e−2σxc)+ e2ucxc
2(σ + uc)
(
e−2(σ+uc)xc − e−2(σ+uc)
)
(23)
I+x0,1 =
e2ucxc
2(σ + uc)
(
e−2(σ+uc)x0 − e−2(σ+uc)
)
(24)
Jx0,1 ≡
∫ 1
x0
y.
′
ψ(y′)
∫ y′
0
z. ψ(z)
z(1− z) = J
+
x0,1
Θ(x0 − xc) + J−x0,1 Θ(xc − x0) (25)
J−x0,1 = (G(x0, σ)−G(xc, σ))−
F (0, σ)
2σ
(
e−2σx0 − e−2σxc) (26)
+ e2ucxc (G(xc, σ + uc)−G(1, σ + uc))
+
e2ucxc
2(σ + uc)
(
e−2(σ+uc)xc − e−2(σ+uc)
)
(F (xc, σ)− F (0, σ)− F (xc, σ + uc))
J+x0,1 =
e2ucxc
2(σ + uc)
(
e−2(σ+uc)x0 − e−2(σ+uc)
)
(F (xc, σ)− F (0, σ)− F (xc, σ + uc))
+ e2ucxc (G(x0, σ + uc)−G(1, σ + uc)) (27)
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J0,x0 ≡
∫ x0
0
y.
′
ψ(y′)
∫ y′
0
z. ψ(z)
z(1− z) = J
+
0,x0
Θ(x0 − xc) + J−0,x0 Θ(xc − x0) (28)
J−0,x0 = (G(0, σ)−G(x0, σ))−
F (0, σ)
2σ
(
1− e−2σx0) (29)
J+0,x0 = (G(0, σ)−G(xc, σ))−
F (0, σ)
2σ
(
1− e−2σxc) (30)
+ e2ucxc (G(xc, σ + uc)−G(x0, σ + uc))
+
e2ucxc
2(σ + uc)
(
e−2(σ+uc)xc − e−2(σ+uc)x0
)
(F (xc, σ)− F (0, σ)− F (xc, σ + uc))
The solutions include the following functions
F (x, σ) ≡ ExpEi(2σx)− e2σ ExpEi(−2σ(1− x)), (31)
G(x, σ) ≡ e
−2σx
2σ
F (x, σ) +
1
2σ
log
(
1− x
x
)
(32)
ExpEi(z) ≡ −
∫ ∞
−z
t.
e−t
t
(33)
where we also used the following identities,
F (x, σ) = −e−2σF (1− x,−σ) and G(x, σ) = G(1− x, σ). (34)
Finally, 〈T 〉x0=xc can be evaluated numerically and maximized with respect to
xc to find this critical control threshold. The result is shown in Figure S4 and
is compared to the corresponding result of the cost-to-go backwards iteration
for the discrete system.
7 Minimal model of drug resistance in cancer
The qualitative aspects of the minimal cancer model introduced in the main
text can be analyzed using a system size expansion [29], with the carrying
capacity K as a large parameter. The expansion entails the parameter scaling
K →∞ with γ ≡ Kg, σ ≡ Ks, µ ≡ Kµ0, φs,r ≡ Kfs,r const. (35)
together with a scaling of time via τ = t/N (with t measured in generations,
i.e. Poisson population updates). The typical relative scale of the model
parameters is
K  φ > γ  σ, µ ≥ 0. (36)
20
Σ = 1
Σ = 5
Σ = 10
Σ = 15
Σ = 20
-40 -30 -20 -10 0
0.0
0.2
0.4
0.6
0.8
1.0
uc
x
c
Figure S4: The control-switch frequency xc(uc, σ) found by maximizing the analytical
expression for the mean survival time (solid lines) and by backwards iteration of eq. 2
in the main text. Note that xc(−2σ, σ) = 0.5.
The expansion of birth and death rates in K is as follows:
Bs(xs, xr) =
(K + γ + σ)K xs
K + γ (xs + xr) + σ xs
+ µ(xr − xs)
= K xs + γ xs (1− xs − xr) + σ xs (1− xs) + µ(xr − xs) +O
(
K−1
)
≡ K xs + bs(xs, xr) +O
(
K−1
)
(37)
Br(xr, xs) = K xr + γ xr (1− xs − xr)− σ xs xr + µ(xs − xr) +O
(
K−1
)
≡ K xr + br(xs, xr) +O
(
K−1
)
(38)
Ds(xr, xs) = K xs + uφs xs, Dr(xr, xs) = K xr + (1− u)φr xr (39)
The differential growth rate σ and the drug-related death rates φs,r break the
symmetry of the model, such that there is no closed growth law for the total
population size N = ns + nr alone: even ignoring boundary terms (at ns = 0
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Figure S5: For finite time ∆ between consecutive measurements, the pre-emptive
control aims for a safe position xsafe away from the boundaries (boundary between
blue and orange) by switching to a neutral regime (u = −σ) after a certain waiting
time (coloring, see legend). At xsafe, the waiting time to neutral is zero, i.e. the system
is immediately set to neutral. As ∆ becomes bigger, xsafe moves from xc ≈ 0.644 to
0.5 and the control strategy shifts from playing-to-win to playing-not-to-lose.
and nr = 0) the tumor size would evolve according to
∆N ∼ Skellam(Bs +Br, Ds +Dr) (40)
〈∆N〉 = Bs +Br −Ds −Dr = bs + br − ds − dr
= γ x(1− x) + σ xs (1− x)− uφs xs − (1− u)φr xr +O
(
K−1
)
(41)
with x ≡ xs + xr = N/K. The role of K as carrying capacity (for
u = 0, φr = 0) is now apparent via 〈∆N〉(x = 1) = 0. The Fokker-Planck
equation for this model in the variables (xs, xr) is given by
∂τP (xs, xr, τ) =
[−∂xs(bs − ds)− ∂xr (br − dr) + (∂2xs + ∂2xr) (xs + xr)]P (xs, xr, τ)
(42)
The form of the birth and death rates above suggests a transformation of
variables.
(xs, xr)→
(
x ≡ xs + xr, y ≡ xs
xs + xr
)
⇒ (xs = x y, xr = x(1− y)) (43)
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The time evolution of the mean values of these new variables is now given
by [29]
∂τ 〈x〉 = 〈bs + br − ds − dr〉
= 〈(γ + σy)x(1− x)− x(uφsy + (1− u)φr(1− y))〉 (44)
∂τ 〈y〉 = 〈1− y
x
(bs − ds)− y
x
(br − dr)〉
= 〈(σ − uφs + (1− u)φr) y(1− y) + µ(1− 2y)〉 (45)
The evolution of the mean relative fraction 〈y〉 of sensitive cells is equivalent
to the evolution of the mean value of the polymorphism frequency within the
controlled one-locus two-alleles Wright-Fisher model discussed earlier (see
eq. 11).
7.1 Numerical test of the cost-to-go calculation
An optimal control strategy fulfilling eq. 8 in the main text can be found
numerically by backwards iteration of the cost-to-go recurrence equation 9
using the exact discrete propagator W (n′s, n
′
r | ns, nr) defined by the Skellam
distribution implicit in eq. 7. To test the sanity of the resulting profile
u¯(xs, xr), we can evaluate the associated cost function directly using a large
ensemble of forward simulations. It should be noted that due to memory and
time limitations, the backwards iteration can only be performed with a rather
small system size of the order max(ns, nr) ≤ 103. For the forward simulations,
only the milder time restriction holds, such that K ∼ O (104) is possible. To
make the two results comparable, it is necessary to use the same scaled
parameters σ = Ks etc. In Figure S6, we compare the probability that
metastasis has not yet occurred by time T = 1/ν (the control objective to be
maximized) as predicted by the cost-to-go calculation with the direct
observation of this event in 103 forward simulations with K = 104 in the
parameter setting of Figure 2A in the main text.
7.2 Uniform expansion of the Skellam distribution
The probability mass function of the Skellam distribution with parameters
(µ1, µ2) is given by
n1 ∼ Pois(µ1), n2 ∼ Pois(µ2) ⇒ n ≡ n1 − n2 ∼ Skellam(µ1, µ2), n ∈ Z
with Skellam(n | µ1, µ2) = e−µ1−µ2
(
µ1
µ2
)n/2
I|n| (2
√
µ1µ2) . (46)
The modified Bessel function In(z) could, in principle, be evaluated for fixed z
via the following recurrence relation,
In−1(z)− In+1(z) = 2n
z
In(z). (47)
23
0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
predicted Hcost-to-go with K=500L
m
e
a
s
u
re
d
H10
3
fw
.
s
im
.
w
it
h
K
=
1
0
4
L
Probabilty of no metastasis
Figure S6: Comparison of the predicted probability that metastasis has not yet oc-
curred by time T = 1/ν in a cancer cell population optimally controlled according to
the profile (and parameters) shown in main text Figure 2A to the measured fraction of
104 forward simulations with that property. The prediction follows from the cost-to-go
dynamic programming calculation (see eq.9 in the main text) performed numerically
with K = 500 and N ≤ 750. The forward simulations were carried out with K = 104,
N ≤ 1.5K.
However, due to a lack of numerical stability of this recurrence, we have here
used the uniform expansion of the Bessel function instead [48],
Iν(νz)
ν→∞−−−−→ e
ν η
√
2piν (1 + z2)
1/4
(
1 +O
(
1
ν
))
(48)
with η ≡
√
1 + z2 + ln(z)− ln
(
1 +
√
1 + z2
)
. (49)
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This expansion has the additional benefit that we can simply use it for the
logarithm of the Skellam distribution,
log Skellam (n) ≈ a+ b n+ ‖(n, z)‖ − 12 log ‖(n, z)‖+ |n| log
z
|n|+ ‖(n, z)‖ ,
(50)
with a ≡ −(µ1 + µ2)− 12 log(2pi),
b ≡ 12 log
(
µ1
µ2
)
,
z ≡ 2√µ1µ2,
‖(n, z)‖ ≡
√
n2 + z2.
The quality of this approximation is also implicit in the simulation test results
shown in Figure S6.
7.3 Control with limited information (N only)
The optimal control profiles shown in Figure 2 in the main text are only
applicable with perfect information of the tumor composition (ns, nr). If only
the total population size N can be measured, then there is a different strategy
to make a control decision: compute the reduced propagator
W (Nτ+∆τ | Nτ−∆τ , uτ−∆τ , Nτ ; uτ ) and derive a new control profile that
depends on the last two measurements and the last applied control. This is
clearly an approximation, such that the resulting control protocol can not be
considered optimal in the mathematical sense. In deriving the reduced
propagator, we use the shorthand notation N ′ = Nτ+∆τ , N = Nτ ,
M = Nτ−∆τ , u = uτ , v = uτ−∆τ and n = ns.
W (N ′ | N, M, v; u) =
N ′∑
n′=0
N∑
n=0
M∑
m=0
W (n′, N ′ − n′ | n, N − n; u)× . . .
(51)
· · · × P (n, N − n | m, M −m, N, v) P (m, M −m |M, N, v)
The first term on the right hand side is the microscopic propagator, expressed
as the product of the two Skellam distributions for ns and nr. The second
term is the probability to go from (m,M −m) to (n,N − n) under control v,
given that the final population size is N ,
P (n, N − n | m, M −m, N, v) = W (n, N − n | m, M −m; v)∑N
k=0W (k, N − k | m, M −m; v)
. (52)
The third and last term is the probability that the system was at (m,M −m),
given that a transition took place from M to N under control v,
P (m, M −m |M, N, v) =
∑N
n=0W (n, N − n | m, M −m; v)∑M
k=0
∑N
n=0W (n, N − n | k, M − k; v)
. (53)
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All these conditional probabilities can be approximated using the logarithmic
expansion of the Skellam distribution above. For the parameter setting of
Figure 2C in the main text, the resulting control profile is shown in Figure S7.
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Figure S7: Control of a tumor via its total size. In the parameter setting of
Figure 2C, a majority rule would be optimal with perfect information. But
when only the total population size N = ns + nr can be measured, the needed
information is not directly available. The control profile above tries to estimate
the inner composition of the tumor indirectly from the immediate response
N(τ −∆τ) → N(τ) to the presence (u(τ −∆τ) = 1, gray areas) or absence of
the drug (u(τ −∆τ) = 0, white areas). The trajectory shown in the lower panel
is also shown in the control profile above, where thick lines indicate a response
big enough to continue the current drug regimen.
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